It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Some features of ATS will be disabled while you continue to use an ad-blocker.
(visit the link for the full news article)
US scientists have discovered a compound that targets and destroys cancer stem cells, a type of rare cell that some scientists believe are responsible for driving tumour growth, and that appear to be resistant to existing anti-cancer therapies.
Researchers at the Massachusetts Institute of Technology (MIT) and the Broad Institute used a new "high-throughput" screening method that allowed them to test thousands of compounds and identify those that killed cancer stem cells.
According to Dr Kat Arney, senior science information officer, Cancer Research UK:
*This is an important piece of research, as it reveals a way to test for chemicals that can act on stem cells, as well as highlighting a potential new cancer drug."
If people woke up to the one true cause of why the human body fails to regenerate damaged cells correctly, big pharma would become obsolete...
Originally posted by mrmonsoon
This may be totally off topic and I am sorry for that, but......
I wonder if cancer stem-cells could be used for cell/organ re-growth.
Furthermore, since it tends to grow very fast, that could be another key in re-growing organs and such.
Just my 2 cents.
CHICAGO (Reuters) - U.S. researchers have discovered a compound that can kill breast cancer stem cells, a kind of master cancer cell that resists conventional treatment and may explain why many cancers grow back, they reported on Thursday.
The discovery came using a new method of screening for drugs that specifically target and kill cancer stem cells, and it could be used to find drugs targeting other cancer stem cells as well, they said.
Many teams have been looking for ways to destroy these master cancer cells in hopes of making cancer easier to cure.
"There is a lot of evidence to suggest now that these cells are responsible for many of the recurrences that are observed after treatment has stopped," Piyush Gupta of the Massachusetts Institute of Technology and the Broad Institute, whose study appears in the journal Cell, said in a telephone interview on Thursday.